Dipexium Pharmaceuticals Announces Presentation at Raymond James 37th Annual Institutional Investors Conference

02 Mar, 2016, 08:00 ET from Dipexium Pharmaceuticals, Inc.

NEW YORK, March 2, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antimicrobial peptide, today announced that David P. Luci, President & Chief Executive Officer, will present a corporate overview at the Raymond James 37th Annual Institutional Investors Conference in Orlando, Florida, on Wednesday, March 9, 2016 at 8:40 a.m. Eastern Time.

To access the live audio webcast of the presentation, please log on through a link located in the Investor Relations section of Dipexium's website at www.dipexiumpharmaceuticals.com, under the IR Calendar tab. A replay of the webcast will be available for 7 days after the conclusion of the live event.

About Dipexium Pharmaceuticals, Inc.

Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide. Initially, Locilex® is targeted for the treatment of mild infections of diabetic foot ulcers. Based on a compilation of available clinical and microbiology data, Locilex® is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA).

Company Contacts:

David P. Luci President & Chief Executive Officer Dipexium Pharmaceuticals, Inc. 212-269-2834 info@dipexium.com

David Garrett Vice President, Finance & Corporate Development Dipexium Pharmaceuticals, Inc. 212-269-2834 info@dipexium.com

© 2016 Dipexium Pharmaceuticals, Inc.  All rights reserved.

 

SOURCE Dipexium Pharmaceuticals, Inc.



RELATED LINKS

http://www.dipexiumpharmaceuticals.com